Indeed, there is considerable evidence for the deleterious impact of high tumor FOXM1 on patient clinical outcome in ER-positive breast cancers,15,29,30 in HER2-positive breast cancers,31 and in triple negative breast cancers.32 FOXM1 is also a key player in many other cancers, including glioblastoma, ovarian, gastrointestinal, non-small cell lung cancers, and pancreatic ductal adenocarcinoma,6,7,11,14,33,34 for which there are currently few optimal treatments. The gene discussed is FOXM1; the disease is triple-negative breast carcinoma.